William A. Greisner III, M.D., has extensive research experience dating back to 1998. His curriculum vitae and a detailed record of his industry-sponsored clinical research experience are listed here. The entire resume is available as a pdf document which can be downloaded using the link below.
UNDERGRADUATE EDUCATION
Houghton College – Houghton, New York – August 1981-May 1983
The University of Connecticut – Storrs, Connecticut – August 1983-May 1986
MEDICAL EDUCATION
Eastern Virginia Medical School – Norfolk, Virginia – August 1987-May 1991
POSTGRADUATE TRAINING
Medical Center Hospital of Vermont – Burlington, Vermont – July 1991-June 1994
Rhode Island Hospital/Brown University – Providence, Rhode Island – July 1994-June 1996
PROFESSIONAL CERTIFICATIONS
National Board of Medical Examiners – Diplomate – 1992
The American Board of Internal Medicine – Diplomate – 2000
American Board of Allergy and Immunology – Diplomate – 2003
PROFESSIONAL LICENSURES
Connecticut Pharmacy License #06708 – 1986-present
Kentucky Medical License #32610 – 1996-present
EMPLOYMENT EXPERIENCES
Noveck’s Pharmacy – Bristol, Connecticut – Licensed Pharmacist – 1986-1987
Boulevard Pharmacy – Bristol, Connecticut – Licensed Pharmacist – 1986-1987
Allergy & Asthma Associates, P.S.C. – Physician – July 1996-present; President – May 2015-present
D.B.A. Bluegrass Allergy Care (BluegrassAllergyCare.com) – February 2016-present
D.B.A. Bluegrass Allergy Research (BluegrassAllergyResearch.com) – February 2017-present
HOSPITAL APPOINTMENTS
Saint Joseph Hospital – Lexington, Kentucky
Saint Joseph East – Lexington, Kentucky
PROFESSIONAL MEMBERSHIPS
American College of Allergy, Asthma, and Immunology
American Academy of Allergy Asthma and Immunology
Bluegrass Society of Allergy, Asthma & Immunology
Eastern Allergy Conference
PUBLICATIONS – ARTICLES
Bergner A, Greisner WA III, Bergner RK. Metered-dose inhalers: The specified number of sprays – Letters to the Editor. JAMA 269:1506, 1993.
Bergner A, Greisner WA III, Bergner RK. Metered-dose inhalers: Drug delivery over the life of a canister – In reply to Letters to the Editor. JAMA 270:2050-2051, 1993.
Greisner WA III, Settipane GA. Hereditary Factor for Nasal Polyps. Allergy and Asthma Proc 17:283-286, 1996.
Greisner WA III, Settipane RJ, Settipane GA. Co-existence of asthma and allergic rhinitis: A 23-year follow-up study of college students. Allergy and Asthma Proc 19:185-188, 1998.
Greisner WA III, Settipane RJ, Settipane GA. Natural history of hay fever: A 23-year follow-up of college students. Allergy and Asthma Proc 19:271-275, 1998.
Settipane GA, Greisner WA III, Settipane RJ. Natural history of asthma: A 23-year followup of college students. Ann Allergy Asthma Immunol 84:499-503, 2000.
Greisner WA III, Settipane RJ, Settipane GA. The course of asthma parallels that of allergic rhinitis: A 23-year follow-up study of college students. Allergy and Asthma Proc 21:371-376, 2000.
Greisner WA III. Onset of action for the relief of allergic rhinitis symptoms with second-generation antihistamines. Allergy and Asthma Proc 25:81-83, 2004.
de Kam PJ, Zielen S, Bernstein JA, Berger U, Berger M, Cuevas M, Cypcar D, Fuhr-Horst A, Greisner WA, Jandl M, LaBmann S, Worm M, Matz J, Sher E, Smith C, Steven GC, Mosges R, Shamji MH, DuBuske L,…Skinner MA. Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy. Allergy 78:2756-2766, 2023.
de Kam PJ, Zielen S, Bernstein JA, Berger U, Berger M, Cuevas M, Cypcar D, Fuhr-Horst A, Greisner WA, Jandl M, LaBmann S, Worm M, Matz J, Sher E, Smith C, Steven GC, Mosges R, Shamji MH, DuBuske L,…Skinner MA. Response to Correspondence to “Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy”. Allergy 79:1637-1638, 2024.
Bernstein JA, Seth A, Rao M, Katz JC, Singh U, Greisner W, Lierl M, Prince B, Mavunda K, Bernstein CK, Guan T, Nation AJ, Rudman Spergel AK, Togias A, Glazman M. Randomized trial of ultraviolet irradiation units installed in homes of children and adolescents with asthma. J Allergy Clin Immunol Glob 4:100427, 2025.
PUBLICATIONS – ABSTRACTS
Greisner WA III, Settipane RA, Ber DJ, Klein DE. Pituitary adenoma and adenoid cystic carcinoma: Two cases presenting with chronic nasal congestion. Ann Allergy 74:71, 1995.
Greisner WA III, Settipane GA. Hereditary factor for nasal polyps. J Allergy Clinical Immunology 95:205, 1995.
Greisner WA III, Settipane RA, Ber DJ, Klein DE. Pituitary adenoma and adenoid cystic carcinoma: Two cases presenting with chronic nasal congestion. Allergy Proceedings 16:312, 1995.
Greisner WA III, Settipane GA. Hereditary factor for nasal polyps. Allergy Proceedings 16:312, 1995.
Greisner WA III, Settipane RJ, Settipane GA. Frequency of hay fever increases with age: A 23-year follow-up of college students. Ann Allergy 76:82, 1996.
Greisner WA III, Settipane RJ, Settipane GA. Natural history of hay fever: A 23-year follow-up of college students. J. Allergy Clinical Immunology 97:299, 1996.
Greisner WA III, Settipane RJ, Settipane GA. Natural history of hay fever: A 23-year follow-up of college students. Allergy and Asthma Proc 17:364, 1996.
Greisner WA III, Settipane RJ, Settipane GA. Prevalence of active hay fever symptoms: A 23-year follow-up of college students. Allergy and Asthma Proc 18:168, 1997.
Bernstein J, Glazman M, Seth A, Rao M, Katz J, Singh U, Greisner W, Lierl M, Prince B, Mavunda K, Bernstein C, Rudman Spergel A. Ultraviolet Irradiation Units Installed In the Homes of Children With Asthma Reduces Asthma Severity. J Allergy Clin Immunology 147:248, 2021.
Bernstein J, Matz J, Steven G, Greisner W, Cypcar D, Fost A, Powell R, Smith C, Berger M, Berger U, Dirr, L, Bastl M, Bouchal J, Pujol H, Krebs M, Armfield O, DuBuske L, de Kam P. Clinical Trial Experience With a New Pollen Sampling Network in The US. J Allergy Clin Immunology 149:199, 2022.
DuBuske L, Zielen S, Bernstein J, Berger U, Berger M, Cuevas M, Cypcar D, Fuhr-Horst A, Greisner W, Jandl M, LaBmann S, Worm M, Matz J, Sher E, Smith C, Steven G, Oluwayi K, Seybold M, Kramer M, Skinner M, de Kam P. A Tyrosine Adsorbed Modified Grass Allergen + MPL SCIT Demonstrates Clinically Improvement in Combined Symptom and Medication Score in Subjects with Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis. J Allergy Clin Immunology 149:317, 2022.
Lanz M, Greisner W, Caimmi D, Schuster A, Pfaar O, Foss-Skiftesvik MH, Nolte H. Early Improvement Of Nasal Symptoms With House Dust Mite Sublingual Immunotherapy Tablet In Children With Allergic Rhinitis/Rhinoconjunctivitis. J Allergy Clin Immunology 157:288, 2026.
PRESENTATIONS
American College of Allergy and Immunology Annual Meeting. San Francisco, California. November 7, 1994. “Pituitary Adenoma and Adenoid Cystic Carcinoma: Two Cases Presenting with Chronic Nasal Congestion.”
Eastern Allergy Conference. Naples, Florida. April 28, 1995. “Hereditary Factor for Nasal Polyps.”
American College of Allergy, Asthma, and Immunology Annual Meeting. Dallas, Texas. November 14, 1995. “Frequency of Hay Fever Increases with Age: A 23-Year Follow-up of College Students.”
American Academy of Allergy Asthma and Immunology Annual Meeting. New Orleans, Louisiana. March 17, 1996. “Natural History of Hay Fever: A 23-Year Follow-up of College Students.”
Eastern Allergy Conference. Southhampton, Bermuda. April 19, 1996. “Natural History of Hay Fever: A 23-Year Follow-up of College Students.”
New England Society of Allergy. Portland, Maine. October 19, 1996. “Natural History of Hay Fever: A 23-Year Follow-up of College Students.”
Combined Allergy/Immunology Societies Meeting. Acapulco, Mexico. January 18, 1997. “Prevalence of Active Hay Fever Symptoms: A 23-Year Follow-up of College Students.”
Eastern, Southwest and Texas Combined Allergy Conference. Palm Beach, Florida. April 15, 1998. “Co-Existence of Asthma and Allergic Rhinitis: A 23-Year Follow-up of College Students.”
Eastern Allergy Conference. Palm Beach, Florida. May 7, 2000. “Allergic Rhinits with Asthma.”
Eastern Allergy Conference. Key Biscayne, Florida. May 5, 2002. “Onset of Action Models.”
POSTERS
Greisner WA III, Settipane GA. American Academy of Allergy and Immunology Annual Meeting, New York, New York, February 27, 1995. “Hereditary Factor for Nasal Polyps.”
Greisner WA, Settipane GA. First Annual Department of Medicine Research Forum, Brown University, Providence, Rhode Island, June 8, 1995. “Hereditary Factor for Nasal Polyps.”
Greisner WA III, Settipane GA. 3rd Annual Hospital Research Celebration, Rhode Island Hospital, Providence, Rhode Island, October 10, 1995. “Hereditary Factor for Nasal Polyps.”
Greisner WA III, Settipane RJ, Settipane GA. American College of Allergy, Asthma, and Immunology Annual Meeting, Dallas, Texas, November 14, 1995. “Frequency of Hay Fever Increases with Age: A 23-year Follow-up of College Students.”
Greisner WA III, Settipane RJ, Settipane GA. Second Annual Department of Medicine Research Forum, Brown University, Providence, RI, June 5, 1996. “Frequency of Hay Fever Increases with Age: A 23-Year Follow-up of College Students.”
Bernstein J, Glazman M, Seth A, Rao M, Katz J, Singh U, Greisner W, Lierl M, Prince B, Mavunda K, Bernstein C, Rudman Spergel A. American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021. “Ultraviolet Irradiation Units Installed In the Homes of Children With Asthma Reduces Asthma Severity.”
Greisner W, Lanz MJ, Caimmi D, Schuster A, Pfaar O, Foss-Skiftesvik MH, Nolte H. American College of Allergy, Asthma, and Immunology Annual Meeting, Orlando, Florida, November 7, 2025. “House Dust Mite Sublingual Immunotherapy Tablet Impact on Rhinitis Days in Children with Allergic Rhinitis/Rhinoconjunctivitis.”
Lanz MJ, Greisner W, Caimmi D, Schuster A, Pfaar O, Foss-Skiftesvik MH, Nolte H. American Academy of Allergy, Asthma & Immunology Annual Meeting, Philadelphia, Pennsylvania, March 1, 2026. “Early Improvement of Nasal Symptoms with House Dust Mite Sublingual Immunotherpy Tablet in Children with Allergic Rhinitis/Rhinoconjunctivitis.”
Lanz MJ, Greisner W, Caimmi D, Schuster A, Pfaar O, Foss-Skiftesvik MH, Nolte H. Eastern Allergy Conference, Palm Beach, Florida, May 30, 2026. “Early Improvement of Nasal Symptoms with House Dust Mite Sublingual Immunotherpy Tablet in Children with Allergic Rhinitis/Rhinoconjunctivitis.”
Site Principal Investigator. Schering-Plough Corporation. Phase IV Study. P97-293-0469. A Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Treatment of Seasonal Allergic Rhinitis (SAR) in Subjects with Co-Morbid Asthma and a History of Seasonal Exacerbations of Asthma on Medical Resources Utilization (for Asthma and SAR). 1998-1999.
Site Principal Investigator. Schering-Plough Corporation. Phase IV Study. P00187-15. A Double-Blind, Double Dummy Clinical Trail to Evaluate the Efficacy and Safety of Mometasone Furoate Dry Powder Inhaler (DPI) 220 mcg QD Given Once Daily in the Evening and Singulair (Montelukast Sodium) Tablets in Steroid Naive Subjects With Asthma. 2000.
Site Sub-investigator. Health Benchmarks, Inc. Post-marketing Study. RES41176. REACH (A Prospective, Nonrandomized Registry Comparing the Clinical, Humanistic, and Economic Outcomes of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50 mcg with Montelukast 10 mg in Patients Previously Controller-Naive or Prescribed an Inhaled Corticosteroid). 2002.
Site Principal Investigator. Novartis Pharmaceuticals Corporation and Genentech, Inc. Post-marketing Study. CHARIOT (Characterization of Allergic Asthma: A Chart Review In Moderate-to-Severe Disease to Assess Asthma Control, Patient Outcomes and Treatment Study). 2006-2007.
Site Principal Investigator. Novartis. Post-marketing Study. HEORUSV200328. Understanding Refractory Chronic Idiopathic Urticaria (CIU) in the US. 2015.
Site Principal Investigator. Allergy Therapeutics (UK) Ltd. Phase II Study. GrassMATAMPL204. A double-blind randomized parallel group study of three cumulative doses of Grass MATA MPL compared to placebo and Grass MATA in patients with seasonal allergic rhinoconjuncitivitis exposed to grass pollen in Mobile Environmental Exposure Chambers (mEECs) out of the grass pollen season. 2015-2017.
Site Principal Investigator. General Innovations and Goods, Inc./National Institutes of Health (NIH). Pivotal Study. U44-CRE-01. A Double Blind, Randomized, Sham Controlled Trial to Investigate the Effect of the CREON2000A on Asthma Control in Children with Mild to Moderate Persistent Asthma. 2016-2019.
Site Principal Investigator. Stallergenes. Phase III Study. SL75.14. A randomized, double-blind, placebo-controlled, multi-center study of the efficacy and safety of STG320 sublingual tablets of house dust mite (HDM) allergen extracts in adults and adolescents with HDM-associated allergic rhinitis. 2017-2018.
Site Principal Investigator. AstraZeneca. Post-marketing Study. EVA-21277-00. Understanding Patient and Medical Professional Perceptions of, and Preferences for, Biologic Therapy in Severe, Uncontrolled Asthma. 2017-2018.
Site Principal Investigator. AstraZeneca. Observational Study. D3250R00023. The CHRONICLE Study: A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States. 2018-2025.
Site Principal Investigator. AstraZeneca. Observational Study. EVA-23313-00. Cognitive Patient Interviews to Assess an Asthma Risk Screener. 2018.
Site Principal Investigator. AstraZeneca. Observational Study. EVA-24053. A Cross-Sectional and Longitudinal Observational Primary Data Collection Study to Assess the Validity of the US Asthma Impairment and Risk Questionnaire (AIRQ) as a Tool that Identifies Patients with Asthma at Risk for Adverse Outcomes from Uncontrolled Asthma. 2019-2020.
Site Principal Investigator. ALK. Phase III Study. MT-12. A one-year placebo-controlled phase III trial evaluating the efficacy and safety of the house dust mite (HDM) SLIT-tablet in children (5-11 years of age) with HDM allergic rhinitis/rhinoconjunctivitis with or without asthma. 2019-2022.
Site Principal Investigator. Allergy Therapeutics (UK) Ltd. Phase II/III Study. PQGrass309. A randomised, double-blind, placebo-controlled exploratory study to explore the efficacy and safety of PQ Grass 27600 SU in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposure. 2020-2022.
Site Principal Investigator. Pfizer. Expanded Access Study. PF-04965842. Abrocitinib Expanded Access Protocol in Adolescents and Adults with Moderate to Severe Atopic Dermatitis. 2021-2022.
Site Principal Investigator. Teva Branded Pharmaceutical Products R&D, Inc. Phase IV Study. FSS-AS-40139. CONNected Electronic Inhalers Asthma Control Trial 2 (“CONNECT 2”), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older with Asthma. 2021-2022.
Site Principal Investigator. GlaxoSmithKline LLC. Phase IIIa Study. Nimble-206785. A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab (Nimble). 2021-2025.
Site Principal Investigator. Regeneron Pharmaceuticals, Inc. Phase III Study. R1908-1909-ALG-2102. A Randomized, Double-Blind, Placebo-Controlled Study in Cat-Allergic Patients with Allergic Rhinitis Who Live with a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies during Natural Cat Exposure in the Home. 2021-2023.
Site Principal Investigator. GlaxoSmithKline LLC. Phase IIIa. Swift 1-206713 A 52-week, randomised, double-blind, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype (Swift 1). 2021-2023.
Site Principal Investigator. Novartis Pharmaceuticals Corporation. CLOU064A2301 Phase III. A multicenter, randomized, double-blind, placebo-controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urticaria (CSU) patients inadequately controlled by H1-antihistamines (REMIX-1). 2021-2023.
Site Principal Investigator. AstraZeneca LP. D5982C00006. Pivotal Phase III Study. A Randomized, Double-Blind, Active Controlled, Parallel Group, Multicenter 24 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered-Dose Inhaler Relative to Budesonide Metered Dose Inhaler and Open-Label Symbicort Turbuhaler in Participants with Inadequately Controlled Asthma (VATHOS). 2021-2025.
Site Principal Investigator. Amgen Inc. 20190194. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria (INCEPTION). 2022-2023.
Site Principal Investigator. AstraZeneca AB. Phase IIa Study. D7552C00001. A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults with Moderate to Severe Uncontrolled Asthma (FLASH). 2022-2025.
Site Principal Investigator. Allergy Therapeutics (UK) Ltd. Phase III Study. PQGrass306. A randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of PQ Grass in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposure. 2022-2023.
Site Principal Investigator. AstraZeneca AB. Phase IV Study. D5180C00032. A Multicenter, Single-arm, Open-label, Post-Authorization, Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under-Studied Populations in the United States (PASSAGE). 2022-2025.
Site Principal Investigator. Allakos Inc. Phase II Study. AK002-027. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab in Adult Subjects with H-1 Antihistamine Refractory Chronic Spontaneous Urticaria. 2022-2024.
Site Principal Investigator. Allakos Inc. Phase II Study. AK002-018. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Lirentelimab in Adult Subjects with Moderate-to-Severe Atopic Dermatitis Inadequately Controlled by Topical Treatments (ATLAS). 2022-2024.
Site Principal Investigator. GlaxoSmithKline LLC. Phase 3a Study. 212895. A multi-centre, single arm, open-label extension study to evaluate the long-term safety of GSK3511294 (Depemokimab) in adult and adolescent participants with severe asthma with an eosinophilic phenotype from studies 206713 or 213744 (AGILE). 2022-2025.
Site Principal Investigator. Amgen Inc. Phase 3 Study. 20210263. A Phase 3, Open-label, 52-week Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adolescent Subjects Aged >/= 12 to < 18 years With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit. 2023-2024.
Site Principal Investigator. AstraZeneca Pharmaceuticals LP. Phase III Study. D5982C00005. A Randomized, Double-Blind, Parallel Group, Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma (LITHOS). 2023-2025.
Site Principal Investigator. Novartis Pharmaceuticals Corporation. Phase II Study. CLOU064/12201. A one month, investigator and participant blinded study to investigate the efficacy and safety of remibrutinib (LOU064) at multiple dose levels in adult participants with peanut allergy. 2023-2024.
Site Principal Investigator. Teva Branded Pharmaceutical Products R&D, Inc. Phase 3 Study. FpA-AS-30094. A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients with Asthma (FLAIR). 2023-2026.
Site Principal Investigator. Allakos Inc. Phase 1 Study. AK006-001 Part C. A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Sequential, Single- and Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of AK006 in Healthy Subjects and in Subjects with H1 Antihistamine Refractory Chronic Spontaneous Urticaria. 2024-2025.
Site Principal Investigator. GlaxoSmithKline Research & Development Limited. Phase 4 Study. 219871. A prospective, real-world, interventional study to evaluate the effect of mepolizumab on achieving clinical remission in participants with severe asthma (REIMAGINE). 2024-
Site Principal Investigator. Eli Lilly and Company. Phase 3 Study. J2T-MC-KGBT. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/LY3650150 in Adult Participants with Perennial Allergic Rhinitis (PREPARED-1). 2024-
Site Principal Investigator. Regeneron Pharmaceuticals, Inc. Phase IV Study. R668-AS-2373. AIM4: Next Step – Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma (AIM 4 Next Step). 2024-
Site Principal Investigator. Allakos Inc. Phase 1 Study. AK006-001X Part C. An Open-Label Extension Study Evaluating the Safety, Tolerability, PK, Immunogenicity, and Clinical Response of Multiple Doses of IV AK006 in Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001. 2024-2025.
Site Principal Investigator. Nocion Therapeutics, Inc. Phase 2b Study. NOC110-C-202. A Phase 2b, Randomized, Double-Blind, Placebo -Controlled Study to Assess the Efficacy, Safety, and Tolerability of Taplucainium Inhalation Powder (NOC-110) in Adults with Refractory or Unexplained Chronic Cough (ASPIRE). 2024-
Site Principal Investigator. Evommune, Inc. Phase 2b Study. EVO756-CSU001. A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults with Moderate to Severe Chronic Spontaneous Urticaria. 2025-
Site Principal Investigator. Bellus Health, Inc./GlaxoSmithKline Research & Development Limited. Phase 3 Study. BUS-P3-02 (CALM-2). A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2). 2025-
Site Principal Investigator. Celldex Therapeutics, Inc. Phase 3 Study. CDX0159-13. A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU2). 2025-
Site Principal Investigator. Sanofi US Services Inc. Observational (Patient Registry) Study. PIR21191. AIRITY: A hybrid cross-sectional and prospective study to assess patient characteristics, disease burden, disease control, phenotypes, endotypes, and outcomes in a real-world setting in patients with asthma. 2026-
Site Principal Investigator. Celldex Therapeutics, Inc. Phase 3b Study. CDX0159-17. A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13 (EMBARQ-CSU LTE). 2026-